Current Report Filing (8-k)
October 11 2022 - 6:16AM
Edgar (US Regulatory)
0001335105
false
0001335105
2022-10-07
2022-10-07
0001335105
LIXT:CommonStockParValue0.0001PerShareMember
2022-10-07
2022-10-07
0001335105
LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember
2022-10-07
2022-10-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 7, 2022
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
delaware |
|
001-39717 |
|
20-2903526 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
680
East Colorado Boulevard, Suite 180
Pasadena,
California 91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
LIXT |
|
The
Nasdaq Stock Market LLC |
Warrants
to Purchase Common Stock, par value $0.0001 per share |
|
LIXTW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On
October 7, 2022, the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted upon were:
Proposal
1: The election of seven director nominees to the Company’s Board of Directors to serve for a one-year term expiring
at the 2023 annual meeting of stockholders.
Proposal
2: To ratify the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2022.
Proposal
3: To approve a proposal to amend the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) to increase
the number of common shares issuable thereunder by 1,800,000 shares.
The
results of the voting were as follows:
Proposal
1 (election of directors):
Each
of the director nominees to the Company’s Board of Directors was elected as follows:
Nominee | |
Votes For | |
Votes Withheld | |
Broker Non-Votes |
Dr. John Kovach | |
| 7,253,572 | | |
| 664,003 | | |
| 2,930,767 | |
Dr. Stephen Forman | |
| 7,214,029 | | |
| 703,546 | | |
| 2,930,767 | |
Dr. Yun Yen | |
| 7,811,544 | | |
| 106,031 | | |
| 2,930,767 | |
Gil N Schwartzberg | |
| 7,212,012 | | |
| 705,563 | | |
| 2,930,767 | |
Regina Brown | |
| 7,803,957 | | |
| 113,618 | | |
| 2,930,767 | |
Dr. René Bernards | |
| 7,813,148 | | |
| 104,427 | | |
| 2,930,767 | |
Bas van der Baan | |
| 7,809,679 | | |
| 107,896 | | |
| 2,930,767 | |
Proposal
2 (appointment of accounting firm):
Votes For | |
Votes Against | |
Abstain | |
Broker Non-Votes |
10,786,234 | | |
54,345 | | |
7,763 | | |
0 | |
Proposal
3 (amendment of 2020 Plan):
Votes For | |
Votes Against | |
Abstain | |
Broker Non-Votes |
7,661,488 | | |
256,087 | | |
0 | | |
2,930,767 | |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
October 11, 2022 |
LIXTE
BIOTECHNOLOGY HOLDINGS, INC. |
|
(Registrant) |
|
|
|
|
By: |
/s/
JOHN S. KOVACH |
|
|
John
S. Kovach, Chief Executive Officer |
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024